Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Corona Remedies introduces affordable generic version of empagliflozin for type 2 diabetes: Our Bureau, Mumbai Thursday, March 13, 2025, 17:50 Hrs [IST] Corona Remedies Limited ha ...

Mankind Pharma launches affordable empagliflozin in India for diabetes: Our Bureau, Mumbai Thursday, March 13, 2025, 17:30 Hrs [IST] Mankind Pharma has launched its affordable gen ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

The price of empagliflozin, a commonly prescribed diabetes drug, has been slashed by a staggering 90% in India. This ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

The price of commonly used diabetes drug empagliflozin has been slashed by almost one-tenth, with the entry of its generic ...

Mankind Pharma, Alkem Laboratories, Glenmark are some of the companies to have launched, making the drug affordable to most ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...

Mankind Pharma has launched generic versions of diabetes medication Empagliflozin under brand names Empaglyde, Empagreat, and ...

Mankind Pharma has launched a generic version of Empagliflozin in India under the brands Empaglyde, Empagreat, and Dynaduo. The launch breaks cost barriers, offering the medication at competitive ...